XML 29 R18.htm IDEA: XBRL DOCUMENT

Related Parties Transactions

9 Months Ended

Sep. 30, 2021

Related Party Transactions [Abstract]

RELATED PARTIES TRANSACTIONS

12. RELATED PARTIES TRANSACTIONS

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’)		The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)		Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)		Director of the Company
GenePharm Inc. (the “GenePharm”)		Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)		Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)		100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)		Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)		Shareholder of the Company
		Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”)		An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan		Entity controlled by controlling beneficiary shareholder of ABVC

Accounts receivable - related parties

Accounts receivable due from related parties consisted of the following as of the periods indicated:

		September 30,				December 31,
		2021				2020
GenePharm Inc.		$	141,826			$	142,225
Amkey			-				1,210
Total		$	141,826			$	143,435

Due from related parties

Amount due from related parties consisted of the following as of the periods indicated:

		September 30,				December 31,
		2021				2020
Rgene		$	47,756			$	42,911
AsiaGene			-				4,241
BioFirst			1,110				-
BioFirst (Australia)			234,606				373,235
BioHopeKing Corporation			124,625				123,583
LBG USA			675				675
BioLite Japan			150,000				150,000
Keypoint			1,610				1,610
The Jiangs			703				-
Total		$	561,085			$	696,255

(1)

As of September 30, 2021, and December 31, 2020, the Company has advanced an aggregate amount of $47,756 and $42,911 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020. As of September 30, 2021, and December 31, 2020, the outstanding loan balance was $33,431 and $31,684; and accrued interest was $12,704 and $11,227, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene. The respective amount due from Rgene for the nine months ended September 30, 2021 and December 31, 2020 was $1,621 and $0, respectively.

(2)

On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020. As of September 30, 2021, and December 31, 2020, the outstanding loan balance was $0 and $3,560, and accrued interest was $0 and $681, respectively.

(3)

On May 11, 2018, the Company and BioFirst (Australia) entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and are due on demand prior to September 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan will be matured on September 30, 2021 with an interest rate of 6.5% per annum. On September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. As of September 30, 2021 and December 31, 2020, the aggregate amount of outstanding loan and accrued interest was $234,606 and $373,235, respectively.

(4)

On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the “BHK”) entered into a co-development agreement, (the “BHK Co-Development Agreement”, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of September 30, 2021 and 2020, due from BHK was $124,625 and $123,583, respectively.

(5)	On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of September 30, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.

(6)

On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan’s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of September 30, 2021 and December 31, 2020, the outstanding advance balances was $150,000 and $150,000, respectively.

(7)

On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. The amount was settled during the third quarter of 2021. As of September 30, 2021 and December 31, 2020, the outstanding loan balance was $1,610 and $1,610, respectively.

(8)	In January 2021, the Company has advanced funds to the Jiangs. The advances bear 0% interest rate and are due on demand. As of September 30, 2021 and December 31, 2020, the outstanding advance balances was $703 and $0, respectively

Due to related parties

Amount due to related parties consisted of the following as of the periods indicated:

		September 30,				December 31,
		2021				2020
BioFirst Corporation		$	19,611			$	23,647
BioFirst (Australia)			59,392				-
AsiaGene			24,017				-
YuanGene			9,205				9,205
The Jiangs			18,750				16,627
Due to shareholders			167,294				166,261
Due to employee			-				72,704
Total		$	298,269			$	288,445

(1)	Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of September 30, 2021 and December 31, 2020, the aggregate amount of outstanding balance and accrued interest is $19,611 and $23,647, respectively.

(2)	As of September 30, 2021, and December 31, 2020, BioFirst (Australia) has advanced the Company an aggregate amount of $59,392 and $0, respectively for new project purpose.

(3)	As of September 30, 2021, and December 31, 2020, AsiaGene has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest rate and is due on demand.

(4)	As of September 30, 2021, and December 31, 2020, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.

(5)	Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of September 30, 2021, and December 31, 2020, the outstanding balance due to the Jiangs amounted to $18,750 and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.

(6)

Since 2018, the Company’s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As of September 30, 2021 and December 31, 2020, the outstanding principal and accrued interest was $167,294 and $166,261, respectively. Interest expenses in connection with these loans were $5,679 and $5,440 for the three months ended September 30, 2021 and 2020, respectively. Interest expenses in connection with these loans were $16,670 and $17,430 for the nine months ended September 30, 2021 and 2020, respectively.

(7)

Commencing January, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted to $0 and $72,704 as of September 30, 2021 and December 31, 2020, respectively. This loan bears interest rate of 1.5% per annum, and the loan with interest has been paid off during the third quarter of 2021.